This is to inform you that pursuant to Regulation 30 & Regulation 33 of Securities Exchange Board of India (Listing Obligation and Disclosure requirement) Regulation 2015 'Listing regulation' ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.5 pts less than Nifty Microcap 250 and 5.0 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Pentokey Organy (India) Limited, a pharma and pesticides trading company, announced its Q3 FY26 (Dec 2025) results. Revenue from operations for the quarter stood at negative Rs 209.14 lakh, indicating a reversal or credit note during the quarter, compared to Rs 98.33 lakh in the previous quarter. Despite this, the company reported a profit of Rs 33.41 lakh for the nine months ended Dec 2025, up significantly from Rs 18.90 lakh in the same period last year. The quarter alone swung to a loss of Rs 29.30 lakh versus a profit of Rs 14.23 lakh in Q2 FY26, dragging Q3 EPS to negative Rs 0.47. The statutory auditors (Verma Mehta & Associates) issued an unmodified review report. The company also disclosed an outstanding income tax demand of Rs 171.58 lakh for AY 2015-16, which is under appeal.
The sharp negative revenue in Q3 is a red flag and suggests possible product returns, pricing reversals, or a one-time accounting adjustment, which may concern short-term investors. However, the nine-month performance remains strongly profitable with healthy growth. Shareholders should watch for clarity on the Q3 revenue reversal and the pending tax dispute of Rs 171.58 lakh.